Monograph
P01AX06 - Atovaquone |
Propably not porphyrinogenic |
PNP |
Rationale
Not significantly metabolised.
Chemical description
Antibiotic used in acute treatment of Pneumocystis carnii- pneumonia (PCP) of moderate severity in patients that cannot tolerate trimethoprim - sulfamethoxazol. Admiistered as oral susspsion 1500 mg daily for 21 days Highly lipophilic substance with restricted bioavailability. Clinically efficient plasma concentration is 15 mg/ml. Excreted in unchanged form in stool. South African list: No data/avoid
IPNet drug reports
Uneventful use reported in 4 patients with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Luxembourg© NAPOS 2024